www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
www
Search
Tuesday, June 27th, 2017
Table of Contents

1 Introduction
5 PMID
 [F] Diseases Research  / PubMed Research Articles  /
PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.

PubMed

 

Resource

The International journal of biological markers 2017 Jun 17; ()

Authors

Wei W1; Zou Y2; Jiang Q3; Zhou Z4; Ding H5; Yan L6; Yang S7;

Author Information
  • 1Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 2Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 3Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 4Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 5Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 6Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.
  • 7Department of Breast Cancer, The Third Hospital of Nanchang City, Nanchang, Jiangxi - PR China.

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by advanced disease stage and poor prognosis. Moreover, due to the lack of therapeutic markers, TNBC patients can't benefit fully from currently available targeted therapies.

METHODS: To fully understand the molecular basis of TNBC, we used gene set enrichment analysis (GSEA) to screen out the most altered functional module in TNBC, from publicly available microarray data and studied the association of the candidate gene with TNBC development.

RESULTS: We found that the proteasome was significantly activated in TNBC. As compared with other breast cancer subtypes and normal tissue, proteasome subunit beta 5 (PSMB5), the key regulator of proteasome function, was overexpressed in TNBC tissue and predictive of poor prognosis. Moreover, we also found that PSMB5 knockdown induced TNBC apoptosis and significantly enhanced cancer cell sensitivity to the chemotherapeutic agents bortezomib and paclitaxel.

CONCLUSIONS: Our results suggest a potential role for PSMB5 as a biomarker and therapeutic target for TNBC.



PMID

28623645

Others

Publication Type: Journal Article


This article is licensed under the the National Library of Medicine License. It uses material from the PubMed National Library of Medicine Data.


Last Modified:   2016-03-27


Search
All informatin on the site is © www.diseases-diagnosis.com 2002-2016. Last revised: March 27, 2016
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: